Wellington Shields Capital Management LLC Has $21.66 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Wellington Shields Capital Management LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3,757.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 234,507 shares of the biopharmaceutical company’s stock after buying an additional 228,428 shares during the quarter. Gilead Sciences makes up about 1.8% of Wellington Shields Capital Management LLC’s investment portfolio, making the stock its 14th largest holding. Wellington Shields Capital Management LLC’s holdings in Gilead Sciences were worth $21,661,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the 4th quarter valued at $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences in the fourth quarter worth $31,000. Finally, Stephens Consulting LLC increased its position in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. UBS Group upped their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective for the company. Finally, Wolfe Research initiated coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price on the stock. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 311,285 shares of company stock worth $31,284,910 over the last three months. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $113.35 on Friday. The firm has a market cap of $141.16 billion, a P/E ratio of 306.35, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The firm’s 50-day simple moving average is $101.42 and its 200-day simple moving average is $92.47. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.79%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.